Abstract
6091 Background: Third generation AIs [anastrozole(A), exemestane(E), letrozole(L)] are FDA-indicated in postmenopausal women with hormone responsive breast cancer (BrCa). Though not approved for use in males, AI use is described in BrCa, prostate ca, hypogonadism, to prevent gynecomastia, and for short stature in adolescents. This study evaluates how AIs are prescribed to males in a U.S. population. Methods: Deidentified pharmacy claims from Medco Health Solutions, Inc. members continuously eligible from 6/1/2007-11/30/2008 were analyzed. Males with claims for an AI were characterized by age, treatment regimen, other medications used, and specialty of prescriber. AI indication was inferred from these characteristics. Results: Claims from 25,710,785 males were analyzed. Over 4,000 males had a claim for an AI (A = 3,109; L = 904; E = 103) during the target period, comprising 3.6% of all AI prescriptions (Rx); < 18 year-old (yo) n = 772 (median 14); 18-64yo n = 2,747 (median 47) ; ≥ 65 yo n = 597 (median 73...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
